HMGB1 and renal fibrosis: Collectively, our findings show that LM49 treatment can ameliorate renal fibrosis through inhibition of HMGB1‐mediated inflammation and necrosis via binding to Hsp90α, providing strong evidence for its anti‐inflammatory and anti‐fibrotic actions.